Drugs that contain Lasmiditan Succinate
1. List of Reyvow drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Apr, 2025
(2 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(6 days from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 31, 2025 |
NCE-1 date: 2024-02-01
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
More Information on Dosage
REYVOW family patents
11
United States
4
China
4
Japan
3
Korea, Republic of
3
Canada
2
Portugal
2
Spain
2
Brazil
2
Croatia
2
Costa Rica
2
New Zealand
2
Mexico
2
Peru
2
Taiwan, Province of China
2
EA
2
South Africa
2
Ukraine
2
Poland
2
Australia
2
Ecuador
2
Denmark
2
European Union
1
Germany
1
Moldova, Republic of
1
Malaysia
1
Jordan
1
Colombia
1
Dominican Republic
1
Egypt
1
Norway
1
Philippines
1
Austria
1
Argentina
1
Morocco
1
Hong Kong
1
Tunisia
1
Lithuania
1
Hungary
1
Slovenia
1
Israel
1
Chile
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic